RETHINK
LEARNING

This activity will focus on the role of interleukin-17 (IL-17) inhibitors in the treatment of psoriatic arthritis (PsA) patients who showed an inadequate response to conventional disease-modifying antirheumatic drugs (csDMARDs), review the updated treatment guidelines regarding initiation of IL-17 inhibitors, and discuss the clinical evidence to support IL-17 inhibitors. Start Learning

Hear from three of Australia’s top rheumatologists – A/Prof Östör, Dr Tellus and A/Prof Bird – in this videocast-style learning activity. Start Learning

This activity will focus on the management of existing patients diagnosed with RA who are showing incomplete response to conventional disease-modifying antirheumatic drugs (cDMARD) Start Learning

A case study-based activity focusing on patient selection for, and practical aspects of, tyrosine kinase inhibitors in RAI-R DTC. Start Learning

An overview of the development and approval processes of biosimilar medicines in Australia, with practical tips on prescribing and counselling. Start Learning

This activity focuses on defining neuroendocrine tumour (NET) as a cancer, as well as on the signs, symptoms and classifications of NETs.

In this activity, Dr Barton Jennings, MBBS, FRACP, Specialist in Respiratory Medicine and Sleep Disorders, discusses the importance of spirometry testing in general practice and demonstrates how to interpret spirometry results using real patient case studies.   Start Learning

An overview of the development and approval processes of biosimilar medicines in Australia.   Start Learning

This module covers the pathophysiology of PEI, risk factors, signs and symptoms, complications, diagnosis, management strategies, such as treatment with pancreatic enzyme replacement therapy (PERT), including CREON^®.   Start Learning

An overview of the development and approval processes of biosimilar medicines in Australia, with practical tips on dispensing and counselling.   Start Learning